CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions

Expert perspectives on the trial design of and safety data from CRESTONE, which analyzed seribantumab therapy in solid tumors with NRG1 fusions.

Shared insight on key efficacy data from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.

Closing out their review of data from the CRESTONE clinical trial, expert panelists highlight the duration and depth of response with seribantumab therapy.

A brief review of key takeaways from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.

Looking toward the future management of solid tumors with NRG1 fusions, expert panelists consider how the availability of seribantumab therapy may impact their practice.

One of the CRESTONE investigators, Tejas Patil, MD, assistant professor of medicine–medical oncology at the University of Colorado School of Medicine in Aurora, discussed seribantumab in previously treated patients with NRG1 fusion–positive tumors.